Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B

NCT01852435 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT01852435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01852435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B
Lead sponsor
Ruijin Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2013
Completion date
February 28, 2018
Enrollment
648 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, follicular lymphoma grade 3b